Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo
Ji Young Yoo(The University of Texas MD Anderson Cancer Center), Balveen Kaur(Augusta University), Yoshihiro Otani(Okayama University), Yeshavanth Banasavadi‐Siddegowda(Neurological Surgery), Haroon Quadri(Northeast Ohio Medical University), Mitch Phelphs(The Ohio State University), Darlene Bystry(The Ohio State University), Deliang Guo(Wuhan University), Alena Cristina Jaime‐Ramirez(The Ohio State University), Jessica Swanner, Flora Park(Rice University), Feng Geng(The Ohio State University), Bangxing Hong(Augusta University Health), Tae Jin Lee(Augusta University), Mitra Nair, Joseph N. Liu(The Ohio State University Wexner Medical Center)
Cited by 50
Related Papers
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
|Proceedings of the National Academy of Sciences|2006|360
Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth
|Cancer Cell|2015|336
Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1–Mediated Lipogenesis
|Clinical Cancer Research|2016|332
The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis
|Proceedings of the National Academy of Sciences|2009|235
Long-range interaction and correlation between <i>MYC</i> enhancer and oncogenic long noncoding RNA <i>CARLo-5</i>
|Proceedings of the National Academy of Sciences|2014|186